Several other research analysts have also issued reports on AZN. Morgan Stanley restated an overweight rating on shares of AstraZeneca in a report on Wednesday, February 9th. Deutsche Bank Aktiengesellschaft reiterated a buy rating and issued a £115 ($143.66) price objective on shares of AstraZeneca in a research note on Tuesday. UBS Group set a £105 ($131.17) price objective on shares of AstraZeneca in a research note on Monday, March 7th. Jefferies Financial Group set a GBX 9,500 ($118.68) price objective on shares of AstraZeneca in a research note on Friday, April 29th. Finally, JPMorgan Chase & Co. set a £120 ($149.91) price objective on shares of AstraZeneca in a research note on Tuesday. One research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Buy and an average target price of £104.75 ($130.85).
AstraZeneca stock opened at £106.16 ($132.62) on Tuesday. The company has a debt-to-equity ratio of 82.58, a quick ratio of 0.67 and a current ratio of 1.16. AstraZeneca has a 52-week low of GBX 7,556 ($94.39) and a 52-week high of £110 ($137.41). The firm has a 50 day moving average price of GBX 9,900.16 and a two-hundred day moving average price of GBX 9,088.61. The firm has a market cap of £164.49 billion and a price-to-earnings ratio of 1,695.87.
AstraZeneca Company Profile (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- Landstar Systems Stock Can Bottom Down Here
- 3M Stock is Worth a Look Because of the Company it Keeps
- 3 Attractive Mid Cap Swing Trades
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.